Continuing Immunotherapy Beyond Progression Prolongs the Survival of Patients With Extensive‐Stage Small‐Cell Lung Cancer: A Multicenter Retrospective Analysis
Continuation of immunotherapy after standard first-line immunotherapy plus chemotherapy can improve survival in patients with ES-SCLC.
Authors
- Qingfen Dong
- Shuangqing Lu
- Jiling Niu
- Hui Zhu
- Zhuoran Sun
Institutions
- Taian City Central Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cam4.71607
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province